Avidity Biosciences Inc (RNA)

NASDAQ
Currency in USD
31.47
+0.20(+0.64%)
Closed·
Pre Market
31.40-0.07(-0.22%)
·
RNA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual trading volume
Fair Value
Day's Range
30.0732.29
52 wk Range
21.5156.00
Key Statistics
Edit
Prev. Close
31.47
Open
31.59
Day's Range
30.07-32.29
52 wk Range
21.51-56
Volume
2.87M
Average Volume (3m)
1.43M
1-Year Change
-26.01%
Book Value / Share
11.05
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RNA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
67.24
Upside
+113.65%
Members' Sentiments
Bearish
Bullish
ProTips
7 analysts have revised their earnings upwards for the upcoming period

Avidity Biosciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Avidity Bio Company Profile

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company’s pipeline has three programs in registrational clinical trials, such as Delpacibart etedesiran, which is in Phase 3 development stage for the treatment of people with myotonic dystrophy type 1; Delpacibart braxlosiran that is in Phase 1/2 development stage for treating facioscapulohumeral muscular dystrophy; and Delpacibart zotadirsen, which is in the Phase 2 EXPLORE44 open-label extension study for the treatment of Duchenne muscular dystrophy. The company is also developing precision cardiology candidates targeting rare genetic cardiomyopathies, including AOC 1086 for phospholamban cardiomyopathy and AOC 1072 for protein kinase AMP-activated non-catalytic subunit gamma 2 syndrome. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Employees
391

Avidity Biosciences Inc SWOT Analysis


Pipeline Progress
Explore Avidity's innovative RNA therapies targeting rare muscular disorders, with multiple candidates in late-stage trials and potential commercial launches on the horizon
Financial Fortitude
Delve into Avidity's robust financial position, boasting $1.4 billion in cash and funding secured through mid-2027, supporting ambitious development goals
Regulatory Roadmap
Learn about Avidity's strategic pursuit of accelerated approval pathways, potentially expediting time-to-market for key drug candidates in FSHD, DM1, and DMD
Market Momentum
Analyst price targets range from $54 to $96, with a consensus recommendation of 1.38 (Strong Buy), reflecting optimism about Avidity's growth potential
Read full SWOT analysis

Compare RNA to Peers and Sector

Metrics to compare
RNA
Peers
Sector
Relationship
P/E Ratio
−10.3x−4.0x−0.5x
PEG Ratio
4.63−0.150.00
Price/Book
2.9x1.9x2.6x
Price / LTM Sales
424.9x4.8x3.1x
Upside (Analyst Target)
111.3%140.4%45.7%
Fair Value Upside
Unlock11.8%5.7%Unlock

Analyst Ratings

17 Buy
0 Hold
0 Sell
Ratings:
17 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 67.24
(+113.65% Upside)

Earnings

Latest Release
May 08, 2025
EPS / Forecast
-0.90 / -0.88
Revenue / Forecast
1.60M / 2.37M
EPS Revisions
Last 90 days

People Also Watch

11.45
ORIC
+5.05%
55.11
MRUS
+1.10%
15.51
KALV
-3.00%
8.80
DYN
-0.90%
16.55
TVTX
+1.35%

FAQ

What Is the Avidity Bio (RNA) Share Price Today?

The live Avidity Bio share price today is 31.47.

What Stock Exchange Does Avidity Bio (RNA) Trade On?

Avidity Bio is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Ticker (Stock Symbol) for Avidity Bio?

The stock symbol (also called a 'ticker') for Avidity Bio is "RNA."

What Is the Current Avidity Bio Market Cap?

As of today, Avidity Bio market capitalisation is 3.79B.

What Is Avidity Bio's (RNA) Earnings Per Share (TTM)?

The Avidity Bio EPS -3.02 (Trailing Twelve Months).

When Is the Next Avidity Bio Earnings Date?

Avidity Bio's next earnings report will be released on 11 Aug 2025.

Is RNA a Buy or Sell From a Technical Analyst Perspective?

Based on today's Avidity Bio moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Avidity Bio Stock Split?

Avidity Bio has split 0 times. (See the RNA stock split history page for full effective split date and price information.)

How Many Employees Does Avidity Bio Have?

Avidity Bio currently has 391 employees.

What is the current trading status of Avidity Bio (RNA)?

As of 11 Jul 2025, Avidity Bio (RNA) is trading at a price of 31.47, with a previous close of 31.47. The stock has fluctuated within a day range of 30.07 to 32.29, while its 52-week range spans from 21.51 to 56.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.